⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DYAI News
Dyadic International, Inc.
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
globenewswire.com
DYAI
Form 8-K
sec.gov
DYAI
Dyadic Announces Continued Listing on the Nasdaq Capital Market
globenewswire.com
DYAI
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
globenewswire.com
DYAI
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
globenewswire.com
DYAI
Dyadic Expands IP Protection and Business Development Activities in Japan
globenewswire.com
DYAI
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets Ready to Announce with Confidence?
newsfilecorp.com
DYAI
Form 8-K
sec.gov
DYAI
Form 8-K
sec.gov
DYAI
Form 8-K
sec.gov
DYAI